Labs today announced its first company spinout: NanoMed,
Inc. The new company was started by Rob Burgess, PhD, former
Vice President of Research & Development at Zyvex Instruments,
and Gareth Hughes, PhD, former Group Leader of Life Sciences at Zyvex
NanoMed is focused on the application of nanotechnology in
Life Sciences. The company seeks to apply nanoparticle technologies for
the development of research grade reagents and cutting-edge
therapeutics. In addition, NanoMed possesses a strong collection of
nanotechnology platforms that are currently available for licensing.
The new company leverages Zyvex's existing Life Science patents,
proprietary methods, and core technologies.
"We are delighted to obtain assignment of the nanoparticle
dispersion intellectual property from Zyvex Labs," said Rob Burgess,
Ph.D., NanoMed's Co-Founder and Chairman of the Board. "The application
of Zyvex Performance Materials' Kentera and other polymers for
functionalizing carbon nanotubes will play an integral role in
solidifying NanoMed's portfolio of cutting-edge nanotechnologies as
they relate to the biomedical sciences. We look forward to continuing a
productive partnership with Zyvex Labs and Zyvex Performance Materials."
"Rob is a focused leader with outstanding technology
development skills," said Zyvex Founder Jim Von Ehr. "He also has a
proven track record in growing businesses. I expect to see exciting new
products from this new venture."
NanoMed's focus centers around the functionalization and
specific delivery of nanoparticles for applications in various
biomedical markets, including the research, diagnostics, therapeutics,
and veterinary sectors. In collaboration with their strategic partners,
NanoMed researchers have developed promising technologies that will
allow for the effective use of nanotechnology-based solutions to
address a variety of issues across multiple scientific disciplines,
including basic biomedical research and applied science related to
disorders such as cancer and infectious diseases.
Other founders include Rocky Draper, PhD, Professor at the
University of Texas at Dallas, and Ellen Vitetta, PhD, Professor and
Director of the Cancer Immunobiology Center at the University of Texas
Southwestern Medical Center in Dallas.
Posted 22nd August 2007